| Publisher’s Note: Join Fierce Biotech Editors and industry leaders at the Fierce Biotech Summit to network and gain exclusive insights. Don’t miss out — register now!
Fierce Biotech will not publish Monday, Sept. 2, for the Labor Day holiday. We’ll be back in your inbox Tuesday, Sept. 3. |
|
Join IQVIA Patient Suite experts Kevin Landells and Anthony Mikulaschek in this webinar as they explore the flexibility in choosing the right approach for integrating patient technology into your next trial. Whether you opt for an integrated solution or individual technology products, this webinar will guide you through the decision-making process to ensure you’re executing a patient technology strategy that fits your needs.
|
|
Today’s Big NewsAug 30, 2024 |
|
Shape the Future of Life Sciences Entries for the Fierce Life Sciences Innovation Awards are coming to a close September 5th, 2024. Submit your entry & lead the charge in life sciences innovation. Enter now!
|
|
| By Darren Incorvaia,Zoey Becker,Gabrielle Masson Cell engineering biotech Sana Biotechnology is bringing Dhaval Patel, M.D., Ph.D., on board as its first ever chief scientific officer. |
|
|
|
By Nick Paul Taylor Shanghai Allist Pharmaceuticals has bought itself a starring role in China’s KRAS market, paying Jacobio Pharma 150 million Chinese yuan ($21 million) for rights to a near-approval inhibitor of the oncogene and a potentially complementary molecule. |
By Conor Hale In an email to staff, CDER Director Patrizia Cavazzoni, M.D., said the council would replace its AI-related steering committee and policy working groups. |
Sponsored by InMed Pharmaceuticals New disease-modifying drugs, biological pathways and blood-based biomarker tests are among the rapid changes shaping the Alzheimer’s disease landscape |
|
Luminex MAP profiles
Ultrasensitive Simoa
Olink Target 48 Cytokine
|
|
By Kevin Dunleavy At the European Society of Cardiology conference in London, Alnylam presented positive data from the phase 3 HELIOS-B trial which assessed RNA silencer Amvuttra (vutrisiran) as a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). |
Sponsored by Bio-Rad Laboratories In this episode of The Top Line, sponsored by Bio-Rad, Dipika Gurnani delves into the challenges and solutions of quantifying HEK293 DNA in biotherapeutics, a field revolutionizing healthcare for over 350 million patients worldwide. |
By Nick Paul Taylor ReNeuron has joined the long list of biotechs to leave London’s AIM stock market. The stem cell biotech is letting go of its listing after money troubles persuaded it to free itself from the costs and regulatory obligations of the exchange. |
By James Waldron NuCana has seen another of its reworked chemotherapies struggle to prove itself in the clinic, halving the biotech’s stock. |
By Zoey Becker The Inflation Reduction Act features a five-year boost in Medicare Part B reimbursement rates for biosimilars. The measure was intended to boost uptake, but has it worked so far? Drug development consultancy Certara sought to find out in its recent "Boost or Bust?" report. |
By Darren Incorvaia Many microbes are extremophiles, capable of surviving conditions that would spell instant death for you and me. From deep-sea hydrothermal vents to boiling hot springs, these single-celled creatures have evolved special tools to help them thrive in tough places. Researchers have long wanted to harness these tools for human applications. |
By Ayla Ellison,Zoey Becker In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond. |
By Angus Liu Sanofi has suspended distribution of its two flu vaccines in China. BioNTech's ADC partner, DualityBio, has filed for a Hong Kong IPO. UCB will offload some Chinese assets for $680 million. And more. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond. |
|
|---|
|
|
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
